President Donald Trump said on Monday that China is ready to come back to the negotiating table and the two countries will start talking very seriously.Politicsread more
The escalating trade war between Washington and Beijing dominated discussions at the G-7 gathering in France.Politicsread more
China's state media is putting up a brave front as the country's trade war with the U.S. escalated sharply over the weekend.China Economyread more
The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
U.S. stock futures surged Monday morning after President Trump said China is ready to come back to the negotiating table following a phone call Sunday and the two countries...Marketsread more
As Washington and Beijing continue to up the ante in their protracted trade fight, the potential of a recession in the U.S. is now "the biggest concern," according to Standard...US Economyread more
Tensions stemming from the U.S.-China trade war escalated sharply over the last few days, with much happening as Asian markets were shut down for the weekend.China Economyread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Neither the U.S. nor China wants to be seen as the party that derailed trade talks, says William Reinsch of Center for Strategic and International Studies.World Economyread more
China said Friday it will be resuming 25% duties on U.S. autos, and a further 5% on auto parts and components.Asia Marketsread more
World leaders, environmental groups and celebrities have publicly decried the vast swaths of forest being destroyed by the fires.World Newsread more
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people after coming under fire from politicians — but at the end of the day, its CEO told CNBC on Thursday she has a business to run.
"I'm running a business," Mylan's chief executive officer, Heather Bresch, said on "Squawk Box. " "We have over 600 products here in the United States that we got mid-single-digit erosion — decreases. No one was talking about price decreases, but that does happen in the industry to keep medicine affordable."
The price of the EpiPen, a lifesaving medication and delivery system for people with severe allergies, has increased more than 400 percent in the past decade, outraging many parents and prompting senators and Democratic presidential nominee Hillary Clinton to question the pricing process.
Before Bresch appeared on CNBC, the company announced it is reducing the cost of EpiPens through the use of a savings card that will cover up to $300 for the EpiPen 2-Pak. Patients who were previously paying the full price for the EpiPen will have their out-of-pocket cost cut by 50 percent. Mylan also is doubling the eligibility for its patient assistance program.
"The fight on the $300 billion pharmaceutical market is real, and we need to fix it, because it's not sustainable," Bresch said. "We are going to continue to run a business, and we are going to continue to meet the supply and demand that's out there."
Bresch said Mylan subsidizes EpiPens in many parts of the world, but it has invested resources into a broken health-care system in the U.S. and in raising patient awareness.
"We've put hundreds of millions of dollars behind it," Bresch said.